Tessera

At #ESMOGI26, Dr Kozo Kataoka discusses GALAXY data showing postoperative ctDNA can identify colorectal liver metastasis patients most likely to benefit from adjuvant chemotherapy. Watch the interview👉 https://bit.ly/4xxdpmA #CRC #ctDNA #MRD #PrecisionMedicine

ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas - ecancer

Dr Kozo Kataoka speaks to ecancer about the ctDNA status and adjuvant chemotherapy after resection of colorectal liver metastases. The study found that the role

bit.ly

At #ESMOGI26, DrPark Memorial Sloan Kettering Cancer Center discusses GLEAM results. Zolbetuximab + gemcitabine and nab-paclitaxel did not improve survival in CLDN18.2-positive MPC, highlighting the need for better patient selection and combination strategies. Watch the video👉https://bit.ly/3UyJiN6

Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS - ecancer

Dr Wungki Park speaks to ecancer about the phase II GLEAM study, which evaluated zolbetuximab plus gemcitabine and nab-paclitaxel in patients with claudin 18 is

bit.ly

At #ESMOGI26, Josep Tabernero discusses that adagrasib plus cetuximab achieved higher response rates, including more CRs, in previously treated KRAS G12C-mutated mCRC, but did not significantly improve PFS or OS vs chemotherapy. Watch the interview👉https://bit.ly/4qxthTJ

Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer - ecancer

Dr Josep Tabernero speaks to ecancer about the final analysis of the phase III KRYSTAL-10 trial evaluating adagrasib plus cetuximab as second-line treatment for

bit.ly

At #ESMOGI26, Dr Michele Milella discusses targeted intratumoural phosphorus-32 microparticles plus FOLFIRINOX in uLAPC, showing encouraging local disease control and supporting further study of this combined approach. Watch the interview👉https://bit.ly/4gPfULa

P-32 microparticle brachytherapy plus FOLFIRINOX shows promising local control in unresectable pancreatic cancer - ecancer

Dr Michele Milella speaks to ecancer about an open-label, multi-centre, randomised study of TaRgeted intratumoural placement of phosphorous-32 microparticles ad

bit.ly

At #ESMOGI26, Dr Nilo Azad (Hopkins Press) discusses early phase 1 results of dual RAS inhibition with zoldonrasib plus daraxonrasib in heavily pretreated KRAS G12D-mutated metastatic pancreatic cancer, showing encouraging activity and manageable safety. Watch interview👉https://bit.ly/3S6hM94

Zoldonrasib plus daraxonrasib targets KRAS G12D in metastatic pancreatic cancer with promising early results - ecancer

Dr Nilo Azad presents early phase 1 results of a novel dual RAS inhibition strategy using zoldonrasib and daraxonrasib in patients with heavily pretreated metas

bit.ly

At #EHA2026, Prof Martin Schrappe discusses that blinatumomab improved 4-year EFS to 83% vs 70% with intensive chemotherapy in high-risk paediatric B-ALL, while reducing relapse and severe treatment-related toxicities. Watch the interview👉https://bit.ly/3U8C56h

Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival - ecancer

Prof Martin Schrappe speaks to ecancer about a randomized trial that evaluated whether blinatumomab could safely replace highly intensive chemotherapy in childr

bit.ly

At #EHA2026, Prof Marek Trněný (Charles University) discusses phase 2 CHEPA results showing brentuximab vedotin plus CHP and etoposide achieved a 91% ORR and 76% complete metabolic response rate in previously untreated CD30+ PTCL. Watch the interview👉https://bit.ly/4xlUgny #Lymphoma #Haematology

Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas - ecancer

Prof Marek Trněný speaks to ecancer about the phase 2 CHEPA study that evaluated the addition of etoposide to brentuximab vedotin plus CHP (CHEP) in prev

bit.ly

At #EHA2026, Prof Umberto Vitolo discusses phase 3 frontMIND results showing tafasitamab plus lenalidomide and R-CHOP reduced the risk of progression or death by 25% in previously untreated high-risk DLBCL. Watch interview👉https://bit.ly/4cOoYNX #DLBCL #Lymphoma #Haematology

Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma - ecancer

Prof Umberto Vitolo speaks to ecancer about the phase 3 frontMIND trial. This trial evaluated the addition of tafasitamab and lenalidomide to standard R-CHOP

bit.ly

At #EHA2026, Prof Umberto Vitolo discusses updated EPCORE DLBCL-3 results showing fixed-duration epcoritamab achieved a 73% ORR and 63% CR rate in frail, elderly patients with newly diagnosed DLBCL. Watch his interview👉https://bit.ly/4wzkKko #DLBCL #Haematology

Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma - ecancer

Prof Umberto Vitolo speaks to ecancer about the updated results from the phase 2 EPCORE DLBCL-3 trial evaluating fixed-duration epcoritamab monotherapy, a CD3&t

bit.ly

At #EHA2026, Prof Anthony Moorman (Newcastle University) discusses UKBlinPredict, using early MRD response and genetic markers such as IKZF1plus and DUX4 rearrangements to predict relapse risk after blinatumomab in B-ALL. Watch the interview👉 https://bit.ly/3RWO6ex #ALL #Haematology

Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL - ecancer

Prof Anthony Moorman speaks to ecancer about his study that evaluated outcomes in children and young people with chemotherapy-intolerant or resistant disease to

bit.ly

At #EHA2026, Prof Carsten Niemann discusses prospective validation of CLL-TIM, a machine-learning model predicting severe infection or treatment need within 2 years in newly diagnosed, asymptomatic CLL. Watch the full interview👉https://bit.ly/4x2NT8x #CLL #Haematology

CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia - ecancer

Prof Carsten Niemann speaks to ecancer about the first prospective, multicenter validation of the Chronic Lymphocytic Leukemia Treatment-Infection Model (CLL-TI

bit.ly

At #EHA2026, Dr Frederick Chen (Barts Health Archives) discusses UK ITP Registry data showing rapid and robust platelet responses with early romiplostim in acute ITP. Watch the full interview👉https://bit.ly/4cHSLb2 #ITP #Haematology

Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19 - ecancer

Dr Frederick Chen speaks to ecancer about real world evidence from the UK Adult ITP Registry evaluating the thrombopoietin receptor agonist romiplostim in acute

bit.ly

At #EHA2026, Prof Chan Cheah discusses phase 3 SOUNDTRACK F1 results showing surovatamig plus rituximab achieved response rates of 95–100% and CR rates of around 84–85% in previously untreated FL. Watch full interview👉 https://bit.ly/3RTR2si #FollicularLymphoma #Haematology

At #EHA2026, Prof David Kuter (Harvard Medical School) highlights the fatigue burden experienced by patients with chronic ITP, even when platelet counts are stable and bleeding is minimal. Watch hos full interview here👉 https://bit.ly/4gv8Mn8

Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding - ecancer

Prof David Kuter speaks to ecancer about his poster presentation that reports findings from a cross-sectional observational study evaluating fatigue in adults w

bit.ly

At #EHA2026, Prof Claire Harrison (Guy's and St Thomas') discusses results showing selinexor & ruxolitinib improved spleen responses in JAK inhibitor-naive MF, with nearly half achieving at least 35% spleen volume reduction & good survival outcomes. Watch the interview here👉 https://bit.ly/3TZ5Xlu

Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis - ecancer

Prof Claire Harrison speaks to ecancer about results from the phase 3 SENTRY trial evaluating selinexor, an XPO1 nuclear export inhibitor, in combination with r

bit.ly

At #EHA2026, Matthew Davids, MD, MMSc discusses phase 3 BRUIN CLL 322 results showing fixed-duration pirtobrutinib plus venetoclax and rituximab improved PFS vs SoC in previously treated CLL/SLL. Watch his interview👉https://bit.ly/4xYnE3x #CLL #Haematology #Oncology

Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL - ecancer

Dr Matthew Davids speaks to ecancer about results from the phase 3 BRUIN CLL 322 trial evaluating fixed-duration pirtobrutinib, a noncovalent BTK inhibitor, in

bit.ly

At #EHA2026, Prof Fabio Efficace (GIMEMA) discusses the APOLLO trial. Arsenic trioxide plus ATRA improved QoL and reduced fatigue, nausea, vomiting and appetite loss vs chemo in high-risk APL. Watch the interview👉https://bit.ly/4i5qrmt #APL #Haematology #Oncology

Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia - ecancer

Prof Fabio Efficace speaks to ecancer about patient reported outcomes from the phase 3 APOLLO trial evaluating arsenic trioxide in combination with all trans re

bit.ly

At #EHA2026, Dr Johannes Schetelig (TU Dresden) discusses phase 3 results showing ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation. Watch the full interview👉 https://bit.ly/4wUVxll

ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation - ecancer

Dr Johannes Schetelig speaks to ecancer about results from a large randomised controlled phase 3 trial comparing anti T lymphocyte globulin and post transplant

bit.ly

Prof Elias Jabbour (UT MD Anderson Cancer Center) reports strong efficacy with subcutaneous blinatumomab in relapsed/refractory Ph+ ALL at #EHA2026. Watch his full interview👉https://bit.ly/45ZSkoJ #ALL #Hematology #Oncology #Immunotherapy

Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia - ecancer

Prof Elias Jabbour speaks to ecancer about a phase 1/2 study that evaluated a subcutaneous formulation of blinatumomab in adults with heavily pretreated relapse

bit.ly

Prof Liang Wang reports strong efficacy for CD19/CD22 bispecific CAR-T therapy at #EHA2026 for R/R large B-cell lymphoma. Watch the full interview👉https://bit.ly/4fPwfPD #Lymphoma #CART #Hematology #Oncology

At #EHA2026, Prof Wechalekar (University College London Hospitals NHS Foundation Trust) presents results showing anselamimab reduced all cause mortality and cardiovascular hospitalisations in kappa light chain AL amyloidosis with advanced cardiac disease. Watch the interview👉https://bit.ly/4wXPCMI

Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis - ecancer

Prof Ashutosh Wechalekar speaks to ecancer about results from the phase 3 CARES trials evaluating anselamimab, a monoclonal antibody designed to promote clearan

bit.ly

At #EHA2026, Dr Ying Huang reports data for CD19/CD20 CAR-T therapy in r/r B-cell lymphoma, showing a favourable safety profile and high response rates, supporting a more accessible off-the-shelf approach to CAR-T. Watch his interview👉https://bit.ly/4fJKZ2w

First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma - ecancer

Dr Ying Huang speaks to ecancer about the first-in-human trial of LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy for patients with relapsed or refrac

bit.ly

At #EHA2026, Dr Guilherme Perini reports results showing favezelimab plus pembrolizumab improved PFS and DoR vs chemotherapy in PD-1 refractory Hodgkin lymphoma, with similar disease control despite lower response rates. Watch the interview 👉https://bit.ly/4wcq254 #HodgkinLymphoma

At #EHA2026, Dr Saad Usmani reports study results showing daratumumab plus bortezomib, lenalidomide and dexamethasone improved MRD negativity, response depth and PFS in transplant ineligible newly diagnosed MM, with long term benefit. Watch his interview👉 https://bit.ly/4q2bpjv

At #EHA2026, Dr Chiara Sartor reports phase 2 GIMEMA AML2521 results showing venetoclax plus azacitidine achieved high MRD negativity and remission rates in NPM1 mutated AML. Watch her interview👉https://bit.ly/4gf36gP

Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure - ecancer

Dr Chiara Sartor speaks to ecancer about results from the phase 2 GIMEMA AML2521 trial evaluating venetoclax plus azacitidine as a molecular relapse interventio

bit.ly

At #EHA2026, Prof Meletios Dimopoulos reports phase 3 SUCCESSOR-2 results showing mezigdomide plus carfilzomib and dexamethasone significantly improved progression free survival, with higher and deeper responses in relapsed or refractory multiple myeloma, with manageable safety.

At #EHA2026, Prof Christopher Fox (University of Nottingham) reports results showing epcoritamab improved PFS, complete response rates, and durability of response vs chemoimmunotherapy in R/R large B-cell lymphoma. Watch his interview👉https://bit.ly/4fPd6fs

Epcoritamab improves progression-free survival in relapsed or refractory large B-cell lymphoma - ecancer

Prof Christopher Fox speaks to ecancer about results from the phase 3 EPCORE DLBCL-1 trial comparing epcoritamab monotherapy with investigator’s choice ch

bit.ly

At #EHA2026, Dr Benoit Tessoulin (@chunantes.bsky.social) presents subgroup analysis from phase 3 EPCORE FL-1 showing epcoritamab plus rituximab and lenalidomide improved response rates and PFS in R/R lymphoma across key patient subgroups👉https://bit.ly/455XIXg

Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular lymphoma subgroups - ecancer

Dr Benoit Tessoulin speaks to ecancer about a subgroup analysis from the phase 3 EPCORE FL-1 trial evaluating epcoritamab in combination with rituximab and lena

bit.ly

At #EHA2026, Prof Martin Wermke (TU Dresden) discusses phase Ia RevSTAR-123 results evaluating AVC-201-01, a first-in-class switchable allogeneic CD123 CAR-T therapy in relapsed/refractory AML. Watch his interview👉https://bit.ly/4xhPbwn #AML #Haematology #CAR_T

First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML - ecancer

Prof Martin Wermke speaks to ecancer about results from the Phase Ia RevSTAR-123 study evaluating AVC-201-01, a switchable allogeneic CD123-targeted CAR-T

bit.ly